53rd at Third
	885 Third Avenue
	New York, New York 10022-4834
	Tel: +1.212.906.1200 Fax: +1.212.751.4864
	www.lw.com
	FIRM / AFFILIATE OFFICES
	Beijing	Moscow
	Boston	Munich
	Brussels	New York
	Century City	Orange County
	Chicago	Paris
	Dubai	Riyadh
	Düsseldorf	Rome
	Frankfurt	San Diego
	Hamburg	San Francisco
May 18, 2018	Hong Kong	Seoul
	Houston	Shanghai
	London	Silicon Valley
	Los Angeles	Singapore
	Madrid	Tokyo
	Milan	Washington, D.C.

VIA EDGAR AND HAND DELIVERY

Ms. Suzanne Hayes
Assistant Director

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.

Mail Stop 4546
Washington, D.C. 20549

Re:          Kiniksa Pharmaceuticals, Ltd. Registration Statement on Form S-1 (File No. 333-224488)

Dear Ms. Hayes:

On behalf of Kiniksa Pharmaceuticals, Ltd. (the “Company”), we are transmitting this letter in response to an oral comment received from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) on May 18, 2018 with respect to Amendment No. 1 to the Company’s Registration Statement on Form S-1 (“Amendment No. 1”). This letter is being submitted together with the filing of Amendment No. 2 to the Company’s Registration Statement on Form S-1 (“Amendment No. 2”), which has been revised to address the Staff’s comment. The bold paragraph below contains the Staff’s oral comment and is followed by the Company’s response. For the Staff’s convenience, we are also sending, by courier, copies of this letter and marked copies of Amendment No. 2 that reflect changes made from Amendment No. 1.

We note your response to comment one which we reissue in part. Please expand your risk factor to discuss the risk that the concentration of ownership of your Class B common shares may result in your Class A shares being undervalued.

Response: In response to the Staff’s comment, the Company has revised the disclosure on pages 6, 69 and 70 of Amendment No. 2.

May 18, 2018

Page 2

If you have any questions regarding the foregoing responses or the enclosed Amendment No. 2, please do not hesitate to contact me by telephone at (212) 906-2916.

Very truly yours,

/s/ Nathan Ajiashvili

Nathan Ajiashvili

of LATHAM & WATKINS LLP

cc:	Sanj K. Patel, Kiniksa Pharmaceuticals, Ltd.
	Thomas Beetham, Kiniksa Pharmaceuticals, Ltd.
	Johan V. Brigham, Latham & Watkins LLP
	Stephen W. Ranere, Latham & Watkins LLP
	Patrick O’Brien, Ropes & Gray LLP